BIOGEN INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
BIOGEN INC. (BIIB) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $266.90 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-04-29
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $266.90M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $246.40M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $391.20M.
- 2025-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $534.90M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-03-31 | $266.90M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $246.40M 10-Q · filed 2026-04-29 |
| 2025-09-30 | $391.20M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $534.90M 10-Q · filed 2025-10-30 |
| 2025-03-31 | $522.40M 10-Q · filed 2026-04-29 |
| 2024-12-31 | $512.80M 10-Q · filed 2026-04-29 |
| 2024-09-30 | $508.90M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $0.00 10-Q · filed 2025-10-30 |
| 2023-12-31 | $0.00 10-Q · filed 2025-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |